Literature DB >> 18192571

Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction.

M A Miller1, I D Pardo, L P Jackson, G E Moore, J E Sojka.   

Abstract

Functional evaluation of the pars intermedia (PI) is required for the early diagnosis of equine pituitary PI dysfunction (PPID), yet most assays target the hypothalamic-pituitary-adrenal axis, which regulates the pars anterior. In contrast, the PI is regulated by dopaminergic tone from hypothalamic neurons. Loss of dopaminergic inhibition is hypothesized to cause the PI hypertrophy and hyperplasia that result in the clinical manifestations of PPID. Domperidone, a dopamine receptor antagonist, should exacerbate the loss of dopaminergic inhibition in horses with PPID and increase the release of endogenous adrenocorticotrophic hormone (eACTH) by PI melanotrophs. To test this, plasma eACTH concentration was determined in horses with or without clinical signs of PPID at 0, 4, and 8 hours after oral administration of 3.3 mg domperidone/kg. Pituitary glands were evaluated postmortem by histologic grading and morphometry. In the 33 horses, median age, plasma ACTH concentration 8 hours after domperidone, and PI area in median sagittal sections were associated with histologic grade as follows: pituitary grade 1 (normal), n = 3, 7.5 years, 20.0 pg/ml, 0.16 cm(2); grade 2 (focal hypertrophy or hyperplasia), n = 9, 14.5 years, 27.1 pg/ml, 0.27 cm(2); grade 3 (diffuse adenomatous hyperplasia), n = 5, 21.0 years, 64.4 pg/ml, 0.48 cm(2); grade 4 (microadenomas), n = 12, 23.3 years, 128.0 pg/ml, 0.87 cm(2); grade 5 (adenoma), n = 4, 24.9 years, 720.5 pg/ml, 2.1 cm(2). Results suggest that horses with pituitary histologic grade > or =3 respond to domperidone with increased plasma ACTH concentration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18192571     DOI: 10.1354/vp.45-1-26

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  10 in total

1.  Investigation of single and paired measurements of adrenocorticotropic hormone for the diagnosis of pituitary pars intermedia dysfunction in horses.

Authors:  D I Rendle; M Duz; J Beech; T Parkin; A E Durham
Journal:  J Vet Intern Med       Date:  2014-10-13       Impact factor: 3.333

2.  Effect of Age, Season, Body Condition, and Endocrine Status on Serum Free Cortisol Fraction and Insulin Concentration in Horses.

Authors:  K A Hart; D M Wochele; N A Norton; D McFarlane; A A Wooldridge; N Frank
Journal:  J Vet Intern Med       Date:  2016-02-09       Impact factor: 3.333

3.  Adipose tissue dysfunction in obese horses with equine metabolic syndrome.

Authors:  A Reynolds; J A Keen; T Fordham; R A Morgan
Journal:  Equine Vet J       Date:  2019-04-10       Impact factor: 2.888

4.  Equine pituitary pars intermedia dysfunction: Identifying research priorities for diagnosis, treatment and prognosis through a priority setting partnership.

Authors:  Rebecca C Tatum; Cathy M McGowan; Rachel S Dean; Joanne L Ireland
Journal:  PLoS One       Date:  2021-01-04       Impact factor: 3.240

5.  Clinical implications of using adrenocorticotropic hormone diagnostic cutoffs or reference intervals to diagnose pituitary pars intermedia dysfunction in mature horses.

Authors:  Remona Horn; Allison J Stewart; Karen V Jackson; Elizabeth L Dryburgh; Carlos E Medina-Torres; François-René Bertin
Journal:  J Vet Intern Med       Date:  2020-12-24       Impact factor: 3.175

6.  Short-Term Effects of Temperature and Thyrotropin-Releasing Hormone Stimulation on Adrenocorticotropin Stability in Horses.

Authors:  Sophia L Hinrichsen; Ka Y Yuen; Elizabeth L Dryburgh; François-René Bertin; Allison J Stewart
Journal:  Animals (Basel)       Date:  2022-01-28       Impact factor: 2.752

7.  The Gingiva of Horses With Pituitary Pars Intermedia Dysfunction: A Macroscopic Anatomical Evaluation.

Authors:  Anne Maria Nitzsche; Kerstin Fey; Kathrin Büttner; Manuela Gröf; Carsten Staszyk
Journal:  Front Vet Sci       Date:  2022-01-25

8.  Equine pituitary pars intermedia dysfunction: a spontaneous model of synucleinopathy.

Authors:  Jessica S Fortin; Ashley A Hetak; Kelsey E Duggan; Caroline M Burglass; Hailey B Penticoff; Harold C Schott
Journal:  Sci Rep       Date:  2021-08-06       Impact factor: 4.379

9.  Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.

Authors:  Jessica S Fortin; Matthew J Benskey; Keith J Lookingland; Jon S Patterson; Erin B Howey; John L Goudreau; Harold C Schott
Journal:  BMC Vet Res       Date:  2020-09-25       Impact factor: 2.741

10.  Dysregulation of Cortisol Metabolism in Equine Pituitary Pars Intermedia Dysfunction.

Authors:  Ruth A Morgan; John A Keen; Natalie Homer; Mark Nixon; Anna M McKinnon-Garvin; Jodie A Moses-Williams; Sarah R Davis; Patrick W F Hadoke; Brian R Walker
Journal:  Endocrinology       Date:  2018-11-01       Impact factor: 4.736

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.